ePurines, Inc is a drug development startup focused on innovative purinergic signaling- based therapies for obesity, metabolic syndrome, and kidney and liver diseases.
Address: 650 Komas Drive, Suite 104A (Box 11),
Salt Lake City, UT 84108
URL: epurine.com
The products of ePurines address to solve the global problem of diet-induced obesity, and kidney diseases that affect a number of Veterans and general population. ePurines products are directed toward a single G protein coupled receptor (P2Y2) to prevent/treat obesity and a number of kidney and non-kidney related diseases. It is very rare to find such a unique target useful to treat multiple diseases or conditions. Further details of the target and the conditions that can be treated by antagonizing it can be found in the website www.epurine.com
ePurines’ technology platform is based on an understanding of purinergic signaling, mediated by extracellular nucleotides, nucleosides and nucleobases, a rapidly emerging field. This evolving science will assist in the understanding of human (patho)physiology, and provides vast potential for novel drug targets in a variety of disease conditions. ePurines is dedicated to designing, developing and evaluating small molecules that selectively modulate the functions of nucleotide P2 receptors and/or the activity of ecto-nucleotidases, such as CD39, that hydrolyze the ligands of the P2 receptors. Multiple approaches, such as rational drug design and testing, screening of libraries, and the use of Artificial Intelligence and Machine Learning-assisted drug discovery are being used for this.